Iniesta E, Lucas M, Ruiz J, Portela M, Romero-Rodenas P, Tolosa MT, Díaz MC, Martín MÁ, Nieto K, Martínez MD, Lloret J, Mayordomo A, Domato M, Fraguas D. [Eligibility of schizophrenia inpatients to participate in clinical trials].
REVISTA DE PSIQUIATRIA Y SALUD MENTAL 2012;
5:71-8. [PMID:
22854577 DOI:
10.1016/j.rpsm.2011.10.002]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 10/04/2011] [Accepted: 10/14/2011] [Indexed: 11/28/2022]
Abstract
INTRODUCTION
This study assesses the potential eligibility of patients admitted to a psychiatric hospitalisation unit to take part in the major clinical trials based on schizophrenia treatment in clinical practice (CATIE, CUtLASS and EUFEST).
MATERIAL AND METHODS
A retrospective evaluation by consulting the medical records of 241 subjects (59.8% males and 40.2% females, mean age 39.7±13.0 years), admitted consecutively over one year to psychiatric hospitalisation unit with a diagnosis of schizophrenia or another psychosis. The influence of the factors involved in the non-eligibility in each of the clinical trials is analysed using logistic regression analysis.
RESULTS
Only 20.7%, 22.3%, and 22.5% of patients with schizophrenia or another psychosis would be eligible to participate in the CATIE, CUtLASS and EUFEST studies, respectively. The main factors involved in the non-eligibility were polytherapy with anti-psychotics (2 or more) (Odds Ratio (OR): 7.64, 95% confidence interval (CI): 3.06-19.06, P<.001), mental retardation (OR: 16.67, 95% CI: 1.75-166.67, P=.014), and resistance, intolerance or contraindication to any of the anti-psychotics of the study (OR: 3.68, 95% CI: 1.13-11.99, P=.030).
CONCLUSIONS
Three out of every four patients with schizophrenia or another psychosis admitted to a psychiatric hospitalisation unit are not represented in the major clinical trials on schizophrenia treatment.
Collapse